Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Strong endorsement by Dr. Frei indeed. The preclinical results of K-AML presented at the 2017 EHA further confirmed Dr. Frei's opinion.

Conclusion

"Our results suggest Kevetrin is a promising new drug in AML patients treatment, both in wild type and, even more, in TP53 mutated tumors, through different molecular mechanisms, giving more therapeutic alternatives in the treatment of this disease."

http://learningcenter.ehaweb.org/eha/2017/22nd/180680/roberta.napolitano.kevetrin.preclinical.study.of.a.new.compound.in.acute.html

http://www.ipharminc.com/press-release/2017/5/23/cellceutix-anti-cancer-drug-candidates-p53-activity-in-acute-myeloid-leukemia-to-be-presented-by-independent-researchers-at-the-2017-european-hematology-association-annual-meeting